# Nuclide record paper-psmafore-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-psmafore-lancet-2024" ;
  schema:name "PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC"@en ;
  schema:description "In men with advanced prostate cancer who had not yet had chemotherapy but whose disease had grown on one hormone-blocking drug, switching to the radioactive PSMA treatment kept the cancer under control for longer than switching to a different hormone drug."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/39293462/>, <https://pubmed.ncbi.nlm.nih.gov/40680993/> ;
  nuclide:tag "prostate cancer", "radioligand therapy", "randomised trial" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)01653-2> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, et al." ;
  nuclide:related <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/terms/arpi/>, <https://nuclide.cc/people/michael-morris/>, <https://nuclide.cc/people/ken-herrmann/>, <https://nuclide.cc/people/oliver-sartor/>, <https://nuclide.cc/people/karim-fizazi/>, <https://nuclide.cc/isotopes/lu-177/> .